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Aims: Numerous algorithms have been developed to guide warfarin dosing and
improve clinical outcomes. We reviewed the algorithms available for various
populations and the covariates, performances and risk of bias of these algorithms.
Methods: We systematically searched MEDLINE up to 20 May 2020 and selected
studies describing the development, external validation or clinical utility of a
multivariable warfarin dosing algorithm. Two investigators conducted data extraction
and quality assessment.
Results: Of 10 035 screened records, 266 articles were included in the review,
describing the development of 433 dosing algorithms, 481 external validations and
52 clinical utility assessments. Most developed algorithms were for dose initiation
(86%), developed by multiple linear regression (65%) and mostly applicable to Asians
(49%) or Whites (43%). The most common demographic/clinical/environmental
covariates were age (included in 401 algorithms), concomitant medications
(270 algorithms) and weight (229 algorithms) while CYP2C9 (329 algorithms),
VKORC1 (319 algorithms) and CYP4F2 (92 algorithms) variants were the most
common genetic covariates. Only 26% and 7% algorithms were externally validated
and evaluated for clinical utility, respectively, with <2% of algorithm developments
and external validations being rated as having a low risk of bias.
Conclusion: Most warfarin dosing algorithms have been developed in Asians and
Whites and may not be applicable to under-served populations. Few algorithms have
been externally validated, assessed for clinical utility, and/or have a low risk of bias
which makes them unreliable for clinical use. Algorithm development and assessment
should follow current methodological recommendations to improve reliability and
applicability, and under-represented populations should be prioritized.
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1 | INTRODUCTION
Warfarin remains the most commonly prescribed oral anticoagulant
for the management of thromboembolic disorders.1 However, dosing
remains challenging due to warfarin's narrow therapeutic index and
highly variable clinical response. These dosing challenges usually result
in a high frequency of adverse effects (thrombosis and bleeding) as
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well as an increased burden to the patient (e.g. more frequent moni-
toring), which could impact quality of life and lead to treatment
discontinuation of an otherwise highly efficacious drug.2 To better
predict an individual's warfarin dose requirements, numerous dose-
prediction algorithms based on demographic, clinical, environment
and genetic factors have been developed.3,4 Algorithms incorporating
only demographic, clinical and environmental factors have been
designated as clinical and those additionally incorporating genetic
factors as pharmacogenetic.5
The availability of numerous published dosing algorithms provides
a wealth of information but makes navigating the literature to identify
which algorithms to use or recommend, and in which patients/
populations difficult. This task becomes more complicated if it is not
clear if the identified algorithms have low risks of bias, have been
externally validated and/or have been evaluated for clinical utility.
The Clinical Pharmacogenetics Implementation Consortium (CPIC) has
recommended the use of 4 dosing algorithms.1 However, these may
not be applicable to non-Caucasians or for some categories of
patients such as those with international normalized ratio (INR)
targets outside of the 2–3 range.1,6,7
Previous reviews have attempted to describe available dosing
algorithms but most, if not all, have had the main limitation of focusing
on a limited number of algorithms. For example Saffian et al.8
evaluated 16 algorithms but these were only from studies that had:
(i) evaluated the algorithm's predictive ability in the form of a high
resolution scatterplot (observed vs predicted maintenance doses);
(ii) used a validation dataset; and (iii) included at least 5 patients
requiring warfarin at a dose >7 mg/d. Other reviews including those
by Verhoef et al.9 (32 algorithms) and Shendre et al.10 (50 eligible stud-
ies) have been narrative in nature and consequently neither reported a
detailed search strategy nor assessed the risk of bias of included
studies. Additionally, both these narrative reviews included only phar-
macogenetic algorithms and the Shendre et al.10 review additionally
excluded studies that did not involve European or African ancestry
populations. To methodologically assess and describe the knowledge
base accumulated so far, we have undertaken this systematic review,
which includes both clinical and pharmacogenetic algorithms with no
population-based exclusion criteria. Our aim was to accurately and
comprehensively summarize which algorithms are available for which
populations and the covariates (demographic, clinical, environmental,
genetic), performances and the risk of bias of these algorithms.
2 | METHODS
2.1 | Search strategy and selection criteria
A predefined protocol (PROSPERO: CRD42019147995), based on the
principles set in the CHARMS (CHecklist for critical Appraisal and data
extraction for systematic Reviews of prediction Modelling Studies)
checklist,11 and PROBAST (Prediction model Risk Of Bias Assessment
Tool), a tool meant to assess the risk of bias and applicability of
prediction model studies12 was followed. This report adheres to the
Preferred Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) statement (Table S1). MEDLINE records (from 1946 to
22 August 2019) were searched using medical subject headings
(MeSH terms) and text words related to “warfarin”, “algorithm” and
“dosing” (Table S2). A second MEDLINE search was conducted on
20 May 2020 to identify records published after our first search. Lists
of references from the identified studies were hand-searched to
identify further eligible studies. Non-English language studies were
excluded.
Observational (e.g. cohort studies) and interventional
(e.g. randomised controlled trials) studies that developed, validated or
assessed the impact/clinical utility of warfarin dosing algorithms in any
warfarin-treated population were included. For development studies,
those that modelled at least 2 predictor variables (not counting dose
and INR readings for dose-revision algorithms) and either: (i) explicitly
stated in their aims that they were developing a dosing algorithm; or
(ii) reported dosing equations, nomograms, charts, tables, computer
programs etc. that can be used to provide a daily or weekly dose, were
included. In all cases, the included predictors had to have been
reported. Unless enough details pertaining to algorithm development
were available in an external validation or clinical utility assessment
study or elsewhere (corresponding development study, other studies),
external validation or clinical utility assessment studies were excluded.
Additionally, for a clinical utility assessment study to be included, a
comparison between a dosing algorithm with an alternative strategy
(such as existing clinical practice) was a prerequisite. For the purposes
of this review, clinical utility13 was defined as the demonstration that a
dosing algorithm improved the quality of anticoagulation (based on the
time spent in the therapeutic INR range) or lead to better clinical end-
points (such as fewer bleeding episodes). Not to be confused with the
outcome to be predicted in the individual studies (i.e. the stable warfa-
rin dose), the primary outcome of interest in this review was the warfa-
rin dose-prediction algorithm developed, and whether it was externally
validated or evaluated for clinical utility in the included studies.
2.2 | Data extraction and quality assessment
One reviewer (I.G.A.) screened titles and abstracts of the retrieved
bibliographic records for eligibility. For all stages, a second reviewer
(R.O.) independently checked a random 10% of the records to check
for consistency. Disagreements were resolved by consensus and
because the first reviewer was consistent with regard to following
agreed upon criteria, only the first reviewer continued reviewing the
remaining records. A data extraction form was adapted from the
CHARMS11 and PROBAST12 tools, piloted in a subset of randomly
selected included papers and used to extract relevant information
related to participants, predictors, outcome, analysis and results. When
a single publication reported both development and external validation
studies (and/or clinical utility assessments), or multiple algorithms, each
study/algorithm was assessed separately.12 The exception was studies
that reported the warfarindosing.com platform—although this platform
incorporates multiple algorithms, it was not possible to separate the
individual algorithms and so it was considered as 2, the clinical and
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pharmacogenetic Gage algorithms.14 Algorithm updating/extension
studies in which new predictors were added to existing algorithms
were considered as new algorithm development studies.12
To assess the methodological quality of each included develop-
ment or external validation study, the 2 reviewers used the PROBAST
tool.12 Although this tool focuses on prediction models that consider
binary or time-to-event outcomes and studies that use generalized
linear modelling, its authors encourage its use in studies that consider
other outcomes and other machine learning techniques such as those
explored in this review.12 It should, however, be tailored to these
other outcomes/techniques as we did in Tables S3 and S4 and
Figure S1. For reasons detailed in Table S3, emphasis was placed on
the assessment of the risk of bias in the analysis domain. We did not
assess the methodological quality (and performance) of clinical utility
(impact) assessment studies since these have been previously
explored in several systematic reviews and meta-analyses.15–22
2.3 | Data synthesis
This systematic review was qualitative in nature and no attempt to
quantitatively synthesise studies by way of meta-analysis was con-
ducted. Consequently, heterogeneity measures and publication bias
were not explored. The descriptive results (i.e. proportions and
measures of central tendency and dispersion) are presented in
structured tables, graphically and as a narrative summary. Where
appropriate, the results were stratified according to the type of algo-
rithm (clinical vs pharmacogenetic) and ethnic populations for which
they were developed. For the purposes of stratifying by population,
we used the 4 categories (White, Asian, Black and Mixed/Other)
reported by 1 of the largest warfarin-related studies to date, the Inter-
national Warfarin Pharmacogenetics Consortium (IWPC) study.23
Where these race categories were unreported, country was used as a
proxy (for example populations from China were categorized as Asian
while populations from northern Europe as White). Regarding which
algorithm would be relevant to a given population, we arbitrarily
chose a 5% cut-off, i.e. an algorithm that recruited at least 5% of a
given population would be applicable to that population. These
descriptive analyses were conducted in R (version 3.6.1).24 No sensi-
tivity analyses were conducted.
2.4 | Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to
corresponding entries in http://www.guidetopharmacology.org, the
common portal for data from the IUPHAR/BPS Guide to
PHARMACOLOGY.
F IGURE 1 PRISMA flow chart of included studies. aIncludes studies that neither stated in their aims that they were developing/validating a
dosing algorithm nor reported dosing equations, nomograms, charts, tables, or other tools that can be used to provide a daily or weekly dose.
bPrior doses and international normalized ratios not counted
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3 | RESULTS
We aimed to summarize which algorithms are available for which
populations, and the covariates, performances and risk of bias of
these algorithms. Figure 1 illustrates the literature search and selec-
tion process; 10 035 records were identified of which 9435 were
excluded based on the title and abstract. Of 600 full text records
assessed for eligibility, 266 met the eligibility criteria and were
included in the qualitative synthesis. Of these, 205, 123 and 32 arti-
cles, respectively, described algorithm development, external valida-
tion and clinical utility assessment. Some articles described both
algorithm development and external validation (n = 74), algorithm
development and clinical utility assessment (n = 10), external valida-
tion and clinical utility assessment (n = 15) while 5 articles reported
all 3 components (Figure S2). The included articles described the
development of 433 dosing algorithms, 481 external validations and
52 clinical utility assessments, whose characteristics are summarised
in Table 1 and detailed in Tables S5 and S6 (algorithm develop-
ment), Table S7 (external validations), and Table S8 (clinical utility
assessments).
Out of all date ranges investigated, the period during which
most algorithm developments/evaluations were published was
2011–2015 in which 175 (41%), 224 (47%) and 18 (35%) algorithms
were developed, externally validated and assessed for clinical utility,
respectively (Table 1, Figure 2). The median sample sizes for these
studies were 229 (range 18–10 673), 125 (28–2181) and
234 (10–2343), respectively. Children were studied less often—algo-
rithm developments, external validations and clinical utility assess-
ments in children were 11 (3%), 26 (5%) and 3 (6%), respectively.
Asia had the highest number of algorithm developments (n = 175,
40%) and external validations (n = 208, 43%), while North America
had the highest rate of clinical utility assessments (n = 25, 48%).
Most of the developed algorithms included both clinical and genetic
covariates (n = 344, 79%), were mostly for dose-initiation (n = 373,
86%), were developed using multiple linear regression (n = 280,
65%) and presented a regression formula that could be used to
compute a weekly or daily dose (n = 239, 55%). Of the developed
algorithms, 111 (26%) and 30 (7%) algorithms were respectively
externally validated or assessed for clinical utility at least once
(Table S9). The 5 most externally validated algorithms were all dose-
initiation pharmacogenetic algorithms and included those by the
IWPC23 (n = 72 external validations), Gage14 (n = 46), Sconce25
(n = 32), Wadelius26 (n = 20) and Huang27 (n = 19) while the 4 most
clinically assessed algorithms were the Gage pharmacogenetic algo-
rithm14 (n = 8 clinical utility assessments), IWPC pharmacogenetic
algorithm23 (n = 7), Gage clinical algorithm14 (n = 5) and Lenzini
dose revision pharmacogenetic algorithm28 (n = 4). Consequently,
most external validations were conducted on pharmacogenetic
(n = 432 external validations, 90%) and dose initiation (n = 443,
92%) algorithms, algorithms developed using multiple linear regres-
sion (n = 458, 95%) and those that presented a regression formula
(n = 453, 94%). A similar trend was observed for the clinical utility
assessments (Table 1).
3.1 | Study populations
Of the 433 developed algorithms, 186 (43%), 210 (49%), 121 (28%)
and 77 (18%) used datasets that included at least 5% White, 5% Asian,
5% Black and 5% Mixed/Other participants, respectively (Table 1). For
the studies including at least 5% White participants, the median
percentage of White participants was 90% (range 33–100%;
Table S10). Corresponding values for Asian, Black and Mixed/Other
cohorts were 100% (7–100%; Table S11), 14% (5–100%; Table S12)
and 71% (5–100%; Table S13), respectively. Other characteristics
stratified by populations are detailed in Tables S10–S13. For the
developed algorithms that included at least 5% White participants in
their datasets, 54 (29%) and 20 (11%) algorithms were respectively
externally validated and assessed for clinical utility at least once
(Table S14). The corresponding values were 55 (26%) and 10 (5%) for
Asians (Table S15), 34 (28%) and 10 (8%) for Blacks (Table S16), and
14 (18%) and 2 (3%) for Mixed/Other (Table S16). It is important to
note that these algorithms were not always validated in populations
for whom they were developed.
3.2 | Predictors
During algorithm development, all 433 algorithms explored demo-
graphic, clinical, and environmental predictors and for these the
median number of predictors included in the final algorithms was
5 (range 0–23). Conversely, only 346 algorithms explored genetic fac-
tors with the median number of genetic predictors included in the
final algorithms being 3 (range 1–205). The predictors included in at
least 10 algorithms are shown in Figure 3. Age (included in 401 algo-
rithms), concomitant medications (270 algorithms, amiodarone in
201 algorithms), weight (229 algorithms) and sex (141 algorithms)
were the 4 most common demographic/clinical/environmental predic-
tors. Comorbidities were included in 100 algorithms and these
included renal disease (42 algorithms), hepatic disease (40 algorithms),
hypertension (27 algorithms) and diabetes mellitus (26 algorithms).
The genes most frequently included in the pharmacogenetic algo-
rithms were CYP2C9 (329 algorithms), VKORC1 (319 algorithms),
CYP4F2 (92 algorithms) and APOE (11 algorithms). CYP2C9 variants
included CYP2C9*2 (in 206 algorithms), CYP2C9*3 (316 algorithms)
and other variants (64 algorithms), while VKORC1 variants included
VKORC1-1639G > A (270 algorithms), VKORC1 1173C > T, (75
algorithms), VKORC1 3730G > A (20 algorithms) and a number of
others (34 algorithms). Figure S3 shows numbers stratified by the 4
population categories. Age remained the most included demographic/
clinical/environmental predictor in each of the 4 categories, while
CYP2C9 remained the most common predictor in Whites, Blacks and
the Mixed/Other population categories, but was overtaken by
VKORC1 in Asians. The Asian algorithms that included the CYP2C9
gene (n = 153) mostly focused on the CYP2C9*3 variant (n = 149,
97%) as opposed to the CYP2C9*2 (n = 44, 29%) or other CYP2C9
(n = 7, 5%) variants. The corresponding proportions for inclusion of
CYP2C9*3 vs CYP2C9*2 vs other CYP2C9 variants, respectively, were
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TABLE 1 Summary characteristics of algorithm developments, external validations, and clinical utility assessments
Characteristic Algorithm development (n = 433) External validations (n = 481) Clinical utility assessments (n = 52)
Publication year, n (%)
2000 and before 7 (1.6) - -
2001 to 2005 12 (2.8) 3 (0.6) 2 (3.8)
2006 to 2010 75 (17.3) 81 (16.8) 12 (23.1)
2011 to 2015 175 (40.4) 224 (46.6) 18 (34.6)
`2016 to 2020 164 (37.9) 173 (36.0) 17 (32.7)
Sample size, median (range) 229 (18–10,673) 125 (28–2,181) 234 (10–2,343)
Participants (included), n (%)
≥5% white 186 (43.0) 205 (42.6) 36 (69.2)
≥5% Asian 210 (48.5) 277 (57.6) 17 (32.7)
≥5% black 121 (27.9) 115 (23.9) 16 (30.8)
≥5% mixed/other 77 (17.8) 62 (12.9) 2 (3.8)
Adults 422 (97.5) 455 (94.6) 49 (94.2)
Children 11 (2.5) 26 (5.4) 3 (5.8)
Location, n (%)
Africaa 2 (0.4) -
Asiab 2 (0.5) 208 (43.2) 14 (26.9)
Europe 175 (40.4) 55 (11.4) 11 (21.2)
North America 34 (7.9) 121 (25.2) 25 (48.1)
South America 136 (31.4) 21 (4.4) -
Middle East 15 (3.5) 25 (5.2) 2 (3.8)
Oceania 30 (6.9) 8 (1.7) -
Multiple 41 (9.5) 41 (8.5) -
Covariates included, n (%)
Clinicalc only 87 (20.1) 49 (10.2) 11 (21.2)
Genetic onlyd 2 (0.5) - -
Clinicalc and genetic 344 (79.4) 432 (89.8) 41 (78.8)
Application time, n (%)
Dose initiation 373 (86.1) 443 (92.1) 40 (76.9)
Dose revision 41 (9.5) 31 (6.4) 10 (19.2)
Both initiation and revisione 19 (4.4) 7 (1.5) 2 (3.8)
Modelling techniques, n (%)
Artificial neural network 32 (7.4) 2 (0.4) 1 (1.9)
Multiple linear regression 280 (64.7) 458 (95.2) 47 (90.4)
Nonlinear mixed effectsf 14 (3.2) 7 (1.5) 3 (5.8)
Support vector regression 27 (6.2) 2 (0.4) -
Otherg 66 (15.2) 9 (1.9) -
Unclear 10 (2.3) 3 (0.6) 1 (1.9)
Algorithm presentation, n (%)
Computer programh 10 (2.3) 4 (0.8) 4 (7.7)
Nomogram/table 9 (2.1) 3 (0.6) -
Regression formula 239 (55.2) 453 (94.2) 47 (90.4)
None 175 (40.4) 21 (4.4) 1 (1.9)
aExcludes Egypt, which is under Middle East.
bMostly China (131 algorithm developments, 120 external validations and 11 clinical utility assessments). This was followed by South Korea (16 algorithm
developments, 59 external validations and 1 clinical utility assessment) and Japan (10 algorithm developments and 14 external validations).
cClinical includes clinical, demographic, and environmental variables.
dClinical factors also considered during the modelling.
eAll incorporate pharmacokinetic and/or pharmacodynamic techniques.
fUsed to fit pharmacokinetic/pharmacodynamic-based algorithms.
gSee Table S6 for details.
hOr online tool.
ASIIMWE ET AL. 5
99 vs 92 vs 19% (Whites, n = 153 algorithms), 99 vs 96 vs 36% (Blacks,
n = 99) and 88 vs 95 vs 30% (Mixed/Other, n = 64).
3.3 | Predictive performance
A fit accuracy measure (the coefficient of determination, R2) was the
most commonly reported performance measure during both algorithm
development (323 [75% of 433]) and external validation (261 [54% of
481]; Table 2). The R2 value represents the proportion of total
interpatient variability in warfarin dose requirements that can be
jointly accounted for by the variables included in an algorithm. For
algorithm development, the median variability in warfarin dose
explained by included predictors was 43% (range 2–96%). This was
higher (median 45%, range 8–96%) when only pharmacogenetic
algorithms were considered and lower (median 20%, median 2–83%)
when only clinical factors were considered. The CYP2C9 and VKORC1
genes, respectively, accounted for a median of 7% (<1–50%) and
median of 25% (1–59%) of the variability in warfarin dose require-
ments. The R2 performance stratified by race is shown in Table S17.
A consideration of the race-specific proportions in each stratified
analysis (Tables S10–S13) should be made when interpreting the race-
stratified performances. For example, for 24 studies that included at
least 5% Black patients, the proportion of warfarin dose variability
that can be attributed to VKORC1 is 23%. However, these 24 studies
on average included a median of only 13% (range 5–100%) Black
patients. When only the 3 studies that included only Black patients
are considered, the median VKORC1 partial R2 becomes 9% (range
7–10%). These partial R2 values should also be cautiously interpreted
since different computation approaches yield different results
(Figure S1).
Regarding the precision (predictive accuracy) and bias measures,
the most reported measures were the mean absolute and mean
prediction errors, respectively, being reported 137 (32%) and 17 (4%)
times (algorithm development) and 222 (46%) and 144 (31%) times
(external validations). The median mean absolute errors for the
algorithm development and external validations were respectively
1.23 and 1.20 mg/d, with Asians (0.70 and 0.96 mg/d) and Whites
(1.29 and 1.30 mg/d) having lower values when compared to Blacks
(1.55 and 1.39 mg/d). The preferred precision and bias measures
(Table S4) were underreported, each being reported only once and
thrice for algorithm development and external validation, respectively.
Clinical relevance and other fit accuracy, precision and bias measures
are detailed in Tables 2 and S17.
Because most studies reported R2 (a fit accuracy measure), we
carried out a posthoc correlation analysis and included the studies that
reported both the R2 and a precision accuracy measure to determine
whether R2 could be a good proxy of predictive accuracy. For this
F IGURE 2 Algorithm development/
evaluation by publication year
F IGURE 3 Predictors included in at least 10
algorithms. APOE, apolipoprotein E; CYP2C9,
cytochrome P450, family 2, subfamily C,
polypeptide 9; CYP4F2, cytochrome P450, family
4, subfamily F, polypeptide 2; PK parameters,
pharmacokinetic parameters (S-warfarin clearance
and/or distribution volume); INR, international
normalized ratio; VKORC1, vitamin K epoxide
reductase complex subunit 1
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TABLE 2 Performance measures
Measures
Algorithm
development (n = 433)
External
validations (n = 481)
Na Median (range) Na Median (range)
Fit accuracy R2b (%)
All 323 43 (2–96c) 261 39 (<1–86)
Pharmacogenetic 273 45 (8–96) 232 41 (<1–86)
Clinicald 178 20 (2–83) 29 24 (<1–69)
CYP2C9 98 7 (<1–50) - -
VKORC1 114 25 (1–59) - -
Correlation coefficient
All 19 0.65 (0.31–0.82) 101 0.60 (0.03–0.86)
Pharmacogenetic 15 0.65 (0.52–0.79) 97 0.60 (0.03–0.86)
Clinical 4 0.56 (0.31–0.82) 4 0.32 (0.07–0.54)
Precision/predictive
accuracy
Mean absolute error (mg/d)e,f
All 137 1.23 (0.11–2.89) 222 1.20 (0.37–3.70)
Pharmacogenetic 105 1.26 (0.11–1.96) 185 1.18 (0.57–3.30)
Clinical 32 1.10 (0.21–2.89) 37 1.34 (0.37–3.70)
Mean square error (mg2/d2)
All 54 0.02 (0.01–0.74) 4 0.67 (0.60–0.74)
Pharmacogenetic 30 0.02 (0.01–0.10) - -
Clinical 24 0.02 (0.01–0.74) 4 0.67 (0.60–0.74)
Root mean square error (mg/d)
All 14 0.80 (0.10–3.09) 68 1.44 (0.19–4.29)
Pharmacogenetic 6 0.34 (0.10–1.44) 58 1.37 (0.19–4.29)
Clinical 8 1.87 (0.66–3.09) 10 1.77 (0.66–2.33)
Mean absolute percentage error (%)f
All 7 21 (13–54) 37 32 (20–53)
Pharmacogenetic 6 25 (18–54) 34 32 (21–53)
Clinical 1 19 (13–21) 3 34 (20–36)
Unbiased mean absolute percentage
Error (%)
All (clinical) 1 34 3 37 (36–38)
Root mean square percentage error (%)
All (pharmacogenetic) 1 42 5 53 (37–99)
Bias Mean prediction error (mg/d)f






Clinical 8 0.04 (0.01–0.60) 4 −0.59
(−1.01–0.27)
Mean percentage prediction error (%)f
All (pharmacogenetic) 3 4 (3–6) 26 22 (2–76)
Logarithm of the accuracy ratio-derived (%)
All (clinical) 1 <1 3 8 (4–13)
Clinical relevance Patients with predicted dose within 20% of actual (%)
All 132 48 (10–98) 245 43 (0–80)
Pharmacogenetic 95 50 (30–98) 231 42 (0–80)
(Continues)
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purpose, we used the mean absolute error as the predictive accuracy
measure because it was the most reported (its limitations as a
predictive accuracy measure (Table S4) not withstanding). A total of
216 algorithm developments and external validations reported both
these 2 measures, with lower mean absolute errors being moderately
associated with higher R2 values (Pearson's product–moment correla-
tion coefficient −0.390 [95% confidence intervals −0.494 to −0.274],
Figure S4).
Tables 2 and S17 include the performance measures stratified
according to whether algorithms were clinical or pharmacogenetic
(direct comparisons are available for some algorithm pairs in Tables S5
and S7). To directly compare the performances of algorithms stratified
according to the modelling technique and time of application (dose
initiation or dose revision), we summarized the studies that, using the
same dataset, included at least 2 algorithms that differed in these
2 characteristics. As expected, dose revision algorithms generally
performed better than dose initiation algorithms (Table S18). Multiple
linear regression performed comparable to or even better than many
other machine learning techniques (Table S19). Although pharmacoki-
netic/pharmacodynamic algorithms (fitted using nonlinear mixed
effect modelling) performed better than other algorithms, this is
mainly attributable to their dose revision aspects (i.e. when used for
dose initiation, performance was comparable). However, the numbers
of direct comparisons were few, and the performance metrics used
were probably suboptimal (Table S4).
3.4 | Risk of bias
We focused on the assessment of the risk of bias in the analysis
domain (Tables S3, S4, S6, S7 and S20). During algorithm develop-
ment, most developments had the number of participants per
candidate predictor variable ≥20 (n = 203, 47%), did not provide
information on the handling of continuous and categorical predictors
(n = 291, 67%), probably included all enrolled participants in the analy-
sis (n = 229, 53%) and did not provide information on the handling of
participants with missing data (n = 233, 54%; Table S20). Additionally,
many algorithm developments relied on univariable (n = 204, 47%)
and multivariable (n = 208, 48%) analysis during predictor selection,
did not appropriately evaluate algorithm performance (n = 232, 54%),
did not account for model overfitting and optimism in algorithm per-
formance (n = 300, 69%), and did not provide enough information to
assess whether predictors and their assigned weights in the final algo-
rithms corresponded to the results reported in the multivariable analy-
sis (n = 220, 51%). Consequently, only 1 (<1%) algorithm was rated as
having a low risk of bias (unclear n = 26, 6%; high n = 406, 94%).
By contrast, most external validations included at least 100 partic-
ipants with stable dose (n = 329, 68%), all probably appropriately han-
dled continuous and categorical predictors (n = 481, 100%), mostly
analysed all enrolled participants (n = 309, 64%) although many did
not provide enough information on the handling of participants with
missing data (n = 293, 61%). Most (n = 273, 57%) reported the preci-
sion measures we considered appropriate for this review, although
only 8 (<2%) were rated as having a low risk of bias (unclear n = 97,
20%; high n = 376, 78%).
Although we did not focus on the risk of bias in the participant,
predictors and outcome domains, the key risk of bias concerns in
these domains are reported in Tables S6 (algorithm development) and
S7 (external validation). Of note, despite large variability, most algo-
rithm developments (n = 386, 89%) and external validations (n = 433,
90%) provided stable dose definitions and/or referenced previous
publications in which the same were provided. Lastly, for algorithm
development, we also explored whether the outcome of stable dose




development (n = 433)
External
validations (n = 481)
Na Median (range) Na Median (range)
Clinical 37 47 (10–87) 14 48 (26–63)
Patients with predicted dose within 1 mg/d of actual
(%)
All 14 63 (34–92) 47 42 (17–83)
Pharmacogenetic 12 63 (34–92) 34 42 (17–83)
Clinical 2 62 (36–87) 13 42 (22–70)
aN represents the number of algorithms for which the respective measures were explored and reported. For algorithm development, both development
and internal validation cohorts were included, if both reported, although the algorithm was still counted as 1. Results in figures were included if a numerical
value was extractable.
bAlso called the coefficient of determination. For the development cohort, adjusted values used, when reported.
cThe highest R2 reported in Pavani29 as 94%/96%.
dFrom clinical algorithms. For algorithm development, this also includes pharmacogenetic algorithms that reported R2 contributions of clinical factors only.
eIncludes 9 studies reporting median absolute error.
fIn some studies (e.g. Botton,30 You,31 Tan,32 Biss,33 Zhou,34 Lin,35 Xie36) these performance measures were unclear or inconsistent with their definitions
(if available) and/or reported values, in which case a best guess was made. For example, a negative mean absolute error was likely to be a mean prediction
error.
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affect the bias of the algorithm (Asiimwe, unpublished data). Most
algorithm developments (n = 228, 53%) did not incorporate any form
of transformation, while 102 (24%) and 85 (20%) algorithm develop-
ments, respectively, incorporated logarithmic and square root trans-
formations for reasons detailed in Table S21 (for 18 [4%] algorithms,
information was not available). The most common reason provided
was to normalize dose and limit heteroscedasticity (n = 120, 64%)
with only 3 (2%) studies reporting clinical considerations as
justification.
4 | DISCUSSION
To facilitate a literature search of warfarin dosing algorithms by clini-
cians, guideline developers and/or policymakers, we have provided a
comprehensive summary of existing algorithms (n = 433), external val-
idations (n = 481) and clinical utility assessments (n = 52) as well as
described the populations for which they were developed. Using a
threshold of at least 5% inclusion in a dataset, most algorithms were
developed in Asians (49% of developed algorithms) and Whites (43%).
Whereas 28% of the development datasets included Blacks, this
group was under-represented, the median percentage of Black
participants in those datasets being only 14% (Asians and Whites, by
contrast, comprised 100 and 90% [medians] of their corresponding
algorithm development datasets). Similar trends were observed in the
external validations and clinical utility assessments, with these results
echoing previous reports of underrepresentation of minority
groups.6,10 The IWPC23 population categories were reported in the
main results. As a result, Hispanic Caucasians were grouped with
European Caucasians, sub-Saharan Blacks with African Americans,
Indians with Han-Chinese, multiple sub-populations under Mixed/
Other etc.—groupings that simplify results' presentation but may be
inaccurate in the context of personalized medicine. We therefore
included locations (countries) from where the trial populations were
recruited to serve as proxies for these sub-populations, and further
disparities were revealed. For example, despite 28% of the algorithm
developments, 24% of the external validations and 31% of the clinical
utility assessments including at least 5% Blacks, <1% algorithm
developments, <1% external validations and none of the clinical utility
assessments were conducted in sub-Saharan Africa, results that
re-affirm our previous report that very few studies are conducted in
Africa.37
Nonstatistical methods including clinical reasoning and literature
support are recommended when deciding which candidate predictors
to omit, combine or include during multivariable modelling.12 To make
it easier for those developing new or updating existing algorithms, we
also summarised the clinical, demographic, environmental, and genetic
factors that are commonly included in warfarin dosing algorithms. The
4 most common demographic/clinical/environmental predictors were
age, concomitant medications such as amiodarone, weight and sex
being included in 93, 62, 53 and 32% of the 433 algorithms, respec-
tively. By contrast, CYP2C9, VKORC1, and CYP4F2 variants were
respectively included in 95, 92 and 27% of the 346 pharmacogenetic
algorithms. All these are well-established predictors whose mecha-
nisms of action have been previously extensively reported.7,38 In line
with the ethnicity-specific differences in minor allele frequencies of
the various genetic variants, population-specific differences were
observed. For instance, CYP2C9*2 is almost absent in some Asian
populations39 and it was included in only 29% of Asian algorithms that
included the CYP2C9 gene (n = 153; compared to being included in
92% of 153 White algorithms, 96% of 99 Black algorithms and 95% of
64 Mixed/Other algorithms). Other CYP2C9 variants (such as *5, *6,
*8 and *11) were mostly included in Black (36% of 99) and Mixed/
Other (30% of 64) algorithms and less frequently in Asian (5% of 153)
and White (19% of 153) algorithms. Despite a higher inclusion of
these other CYP2C9 variants in studies employing at least 5% Blacks,
36% may still be a low figure given the importance of these African-
specific variants.37 When undertaking multivariable modelling, other
population- and/or clinical setting-specific considerations such as
availability and cost of predictors should also always be considered.12
Our third objective was to evaluate the performances of these
algorithms. As reported previously,40 the coefficient of determination
(R2) was the most common performance measure (reported in 75% of
algorithm developments and 54% of external validations). Based on
R2, the median contribution of clinical factors (20%) and VKORC1
(25%) was similar to previous estimates7,38 although CYP2C9’s
contribution (7%) was lower (previously estimated at 1238 and 15%7).
Among the first of 2 key cautions is, like for all the other performance
measures, these summary estimates were descriptive in nature since
we did not conduct a formal quantitative synthesis, which with the
preferred measures (Table S4) and methods (such as individual partici-
pant data meta-analysis41) is possible. Because of the descriptive
nature of the study, different algorithms using the same or over-
lapping datasets was also of little concern. The second cautionary
warning is that R2 is a fit accuracy and not a prediction accuracy mea-
sure, the former of which is of less relevance when evaluating the
value of prediction algorithms.42–44 For example, fit accuracy mea-
sures will mostly focus on the correct relative ordering of the dose
predictions while predictive accuracy measures will also require that
these predictions be close to the doses actually required by the
patients. During a posthoc correlation analysis aimed at determining if
R2 could be a good proxy of 1 of the predictive accuracy measures
(the mean absolute error, MAE), a moderate correlation coefficient
(−0.39) was observed, which further questions the use of fit-accuracy
measures given that predictive accuracy measures are available.
Among the predictive accuracy distance measures (Table S4), the
MAE is preferred to the [root] mean squared error mainly because it is
less sensitive to outliers45—and this would be an additional reason to
prioritize it over R2, which is also highly sensitive to outliers. For
example, the exclusion of only 1 outlier (<0.1% of 1010 participants)
in the IWPC internal validation cohort improved the performance of
the pharmacogenetic algorithm from an R2 of 33 to 43%23 while in
Langley's study (n = 75), the R2 increased from 9 to 31% when 2 out-
liers were excluded.46 To reiterate and for the reasons above, all the
reported R2 values, especially those that approach 100%, should be
interpreted cautiously. Despite the mean absolute error being
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preferable to the above-mentioned measures, it remains a distance
measure whose limitations we detail in Table S4. In the same table,
we describe an unbiased predictive accuracy ratio measure (derived
from the logarithm of the ratio of the predicted dose to the actual
dose43,47), which we consider to be most appropriate. Unfortunately,
and excluding our own study (Asiimwe, unpublished data), this mea-
sure was not used. We conducted some comparisons in performance
based on populations, modelling techniques and the time an algorithm
is applied but these results should again be cautiously interpreted
because few studies reported direct comparisons and the perfor-
mance measures used were likely to be inappropriate. For example, it
may be misleading to conclude that Asians are better dosed compared
to Whites or Blacks based on mean absolute error (or any distance
measure that ignores the actual dose required by a patient) since as
explained in Table S4, an MAE of 1 mg/d in a small value (e.g. 2 mg/d)
may be clinically more important than a larger error (e.g. 2 mg/d) in an
even larger value (e.g. 5 mg/d). With these precautions in mind, multi-
ple linear regression (the most commonly used technique) seemed to
perform comparable or even better than other supervised machine
learning techniques as previously observed.23 A further understanding
of these other techniques, and a more thorough comparison with mul-
tiple linear regression, is nevertheless recommended. For instance,
artificial neural networks can capture very complex relationships,48
while pharmacokinetic/pharmacodynamic-based techniques model
both temporal and quantitative aspects of warfarin response and do
not exclude unstable patients,40 which may be beneficial to warfarin
dosing.
Lastly, we assessed the risk of bias of existing algorithms with
focus on the analysis domain. Less than 2% of both algorithm devel-
opments and external validations had a low risk of bias. Only our
study was ranked as having a low risk of bias during algorithm devel-
opment and although this could be because of self-evaluation, we
mainly attribute it to following the TRIPOD (Transparent Reporting of
a multivariable prediction model for Individual Prognosis Or Diagnosis)
guidelines,49 which if followed correctly would result in a low risk of
bias rating with the risk of bias assessment tool that we used. It is of
concern that although the TRIPOD guidelines were published in 2015,
none of the other 163 studies reported from 2016 onwards refer to
its use. In the context of not adhering to current methodological rec-
ommendations, warfarin dosing algorithms may not be unique.50,51
The consequences of most of the design flaws have been previously
described in detail.52 One key issue that has received less attention is
data transformation (done in 44% of the algorithm developments). As
discussed by Keene,53 we also discourage data-driven decisions to
transform or not and recommend that the logarithmic transformation
be preferred because it produces a proportional/multiplicative scale
that is clinically relevant and easy to interpret.53,54 A slightly more
complex method to fit nontransformed dose using a proportional/
multiplicative scale is to estimate the parameters of a linear algorithm
using nonlinear (log–log) modelling43,47 as we previously did (Asiimwe,
unpublished data).
In agreement with the CPIC guidelines,1 we recommend the
IWPC23 and Gage14 clinical and pharmacogenetic algorithms since
these have been the most externally validated and clinically assessed
algorithms. Specifically, clinical utility assessments have concluded
that they are better than fixed dose-initiation approaches.15–22
Recent debate has mainly focused on whether pharmacogenetic-
guided dosing strategies are better than clinical-guided strategies with
randomized controlled trials such as Kimmel et al.,55 Pirmohamed
et al.56 and Gage et al.57 providing conflicting results—we neither
quantitatively synthesized (both benefit and safety) nor assessed the
risk of bias of the clinical utility studies since we felt these have been
previously explored in more detail in several systematic reviews and
meta-analyses.15–22
In addition to the CPIC guidance, before using these or other algo-
rithms, clinicians, guideline developers and/or policymakers are
reminded to ensure their applicability to their respective populations.
For example, the above pharmacogenetic algorithms, despite including
Black patients, may not be appropriate for Blacks because they exclude
important Black-specific genetic variants. Clinicians are also reminded
that other numerous dosing algorithms that were not assessed in this
review exist and may be more appropriate depending on the clinical
setting. For example, we excluded many algorithms that rely only on
current dose and measured INR levels to make this review more man-
ageable, while the Food and Drug Administration dosing table was
excluded because themethods used to derive this table are not publicly
available. Nevertheless, these algorithms are less likely to perform
better than those that incorporate predictors additional to existing
dose/measured INR while the Food and Drug Administration table has
been assessed in several studies58–64 and its performance is not better
than the pharmacogenetic algorithms we have reported here.
In addition to using heterogeneous and nonspecific racial catego-
ries, presenting mainly descriptive results, and excluding algorithms
that rely only on current dose and measured INR levels, our study had
other limitations. Specifically, we did not include non-English articles,
which could have affected geographical representation. For example,
we excluded 9 Chinese studies during title/abstract screening and
non-English articles are less likely to be indexed in MEDLINE.65
Although we tried identifying other studies through reference list
searching, using only the MEDLINE database also limited the number
of studies that we could include in this review. Lastly, we relied on
single-reviewer extraction; a second reviewer, nevertheless,
confirmed consistency based on a random selection of 10% of the
included papers.
For further research, novel/existing algorithms may need to be
developed or updated and externally validated following the
recommended guidelines such as TRIPOD.49 More attention needs to
be paid to under-represented populations such as minority ethnic
groups and children (only 3% developed algorithms) to reduce health
disparities. Moreover, although newer directly acting oral anticoagu-
lants have been developed, warfarin is likely to remain the preferred
choice for some of these groups.66
In conclusion, this systematic review provides a comprehensive
summary of the algorithms available for different populations and
their associated covariates (demographic, clinical, environmental
and/or genetic), performances and risk of bias from these algorithms.
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Most of these algorithms have been developed for Asians and Whites,
most have neither been externally validated nor assessed for clinical
utility and either have a high or unclear risk of bias, which makes their
reliability for clinical use uncertain. Future research should focus on
developing prediction algorithms for under-represented populations
and externally validating and assessing the clinical utility of these and
already existing algorithms. Algorithm development and assessment
should follow current methodological recommendations to improve
reliability and applicability.
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